With the evolving consumer demand and rising environmental consciousness, the prospects of the electric vehicle market look ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

Inc., a pharmaceutical company with a market capitalization of $5.67 million, has entered into a definitive agreement with AbbVie (NYSE:ABBV) Bioresearch Center Inc., effectively selling certain ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other ...

So, it's important to know a company's potential revenue growth. For AbbVie, the consensus sales estimate for the current quarter of $12.96 billion indicates a year-over-year change of +5.3%.

one can better assess the future performance of a company Every investor in AbbVie Inc. (NYSE:ABBV) should be aware of the most powerful shareholder groups. The group holding the most number of ...

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma ...